医学
成纤维细胞生长因子受体
成纤维细胞生长因子受体1
癌症研究
转移性尿路上皮癌
成纤维细胞生长因子
酪氨酸激酶抑制剂
酪氨酸激酶
尿路上皮癌
肿瘤科
内科学
受体酪氨酸激酶
癌症
受体
膀胱癌
作者
Yohann Loriot,Andrea Necchi,Se Hoon Park,Jesús García-Donás,Robert Huddart,Earle F. Burgess,Mark T. Fleming,Arash Rezazadeh,Begoña Mellado,Сергей Варламов,Monika Joshi,Ignacio Durán,Scott T. Tagawa,Yousef Zakharia,Bob Zhong,Kim Stuyckens,Ademi Santiago-Walker,Peter De Porre,Anne O’Hagan,Anjali Narayan Avadhani,Arlene Siefker-Radtke
标识
DOI:10.1056/nejmoa1817323
摘要
Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase inhibitor of FGFR1–4, has shown antitumor activity in preclinical models and in a phase 1 study involving patients with FGFR alterations.
科研通智能强力驱动
Strongly Powered by AbleSci AI